Eisai’s Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese drug maker says it now plans to file the AMPA receptor antagonist in fiscal fourth quarter 2008, not fiscal 2007.
You may also be interested in...
Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010
New studies in neuropathic pain and epilepsy employ doses up to 12mg, compared to 2mg and 4mg doses in Parkinson’s studies.
Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010
New studies in neuropathic pain and epilepsy employ doses up to 12mg, compared to 2mg and 4mg doses in Parkinson’s studies.
Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By Bristol-Myers Squibb Drug
Ixempra already cleared for identical breast cancer indication.